Cargando…
Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012–2016)
BACKGROUND: This study reports the global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam using data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program between 2012 and 2016. METHODS: For the 2012–2016 ATLAS program, 205 medical centers located...
Autores principales: | Zhang, Hui, Xu, Yingchun, Jia, Peiyao, Zhu, Ying, Zhang, Ge, Zhang, Jingjia, Duan, Simeng, Kang, Wei, Wang, Tong, Jing, Ran, Cheng, Jingwei, Liu, Yali, Yang, Qiwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590473/ https://www.ncbi.nlm.nih.gov/pubmed/33109242 http://dx.doi.org/10.1186/s13756-020-00829-z |
Ejemplares similares
-
In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program
por: Jia, Peiyao, et al.
Publicado: (2022) -
Performance Evaluation of the Gradient Diffusion Strip Method and Disk Diffusion Method for Ceftazidime–Avibactam Against Enterobacterales and Pseudomonas aeruginosa: A Dual-Center Study
por: Zhang, Jingjia, et al.
Publicado: (2021) -
Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021) -
Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022) -
Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
por: Zhu, Ying, et al.
Publicado: (2021)